1. Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study
- Author
-
Sicras-Mainar A, de Abajo FJ, and Izquierdo-Alonso JL
- Subjects
copd ,triple-therapy ,extrafine particle ,exacerbations ,pneumonia ,health costs. ,Diseases of the respiratory system ,RC705-779 - Abstract
Antoni Sicras-Mainar,1 Francisco J de Abajo,2,3 José Luis Izquierdo-Alonso4,5 1Health Economics & Outcomes Research, Atrys Health, Barcelona, Spain; 2Unidad de Farmacología Clínica, Hospital Universitario Príncipe de Asturias, Madrid, Spain; 3Departamento de Ciencias Biomédicas, Universidad de Alcalá (IRYCIS), Madrid, Spain; 4Departamento de Medicina y Especialidades, Universidad de Alcalá, Madrid, Spain; 5Servicio de Neumología, Hospital Universitario de Guadalajara, Guadalajara, SpainCorrespondence: Antoni Sicras-MainarAtrys Health SA, C/Provença 392, bajos, Barcelona 08025 SpainTel +34 934 581 561Email ansicras@atryshealth.comObjective: To determine the clinical and economic consequences of inhaled corticosteroid doses and particle size in patients on triple-inhalation therapy for COPD.Methods: Patients aged ≥ 40 years who initiated treatment with multi-inhaler triple-inhaled therapy between 1 January 2015 and 31 March were included and followed for 1 year. Patients were grouped according to inhaled corticosteroid (ICS) dose (low/medium/high) and particle size device (extrafine/non-extrafine particles). Outcome variables were moderate and severe exacerbations, pneumonia and healthcare resource use (HCRU) costs. A multivariate analysis was performed for model correction (p< 0.05).Results: A total of 2185 patients (mean age 72.3 years, 82.9% male) were analysed. Of these, 849 (38.9%) patients received low-dose ICS, 612 medium-dose ICS (28.0%) and 724 (33.1%) high-dose ICS. Exacerbations occurred more frequently with increasing IC dose (low: 26.4%, medium: 28.7% and high: 30.4%; p=0.047), as did the proportion of pneumonia (3.4%, 4.2% and 6.9%, respectively (p=0.041)). The annual mean cost/unit was € 2383 for low dose, € 2401 for medium dose and € 2625 for high dose (p=0.024). Four hundred and sixty-two (31.6%) patients used an extrafine particle device and 999 (68.4%) a non-extrafine particle device: the proportion of exacerbations was 24.0% vs 30.4% (p=0.012), and the annual mean cost/unit was € 2090 vs € 2513, respectively (p< 0.001). The number of exacerbations was directly correlated with FEV1 (β= − 0.157), age (β=0.071), Charlson index (β=0.050) and device type (extrafine: β=0.049) (p< 0.02).Conclusion: In patients with COPD receiving multi-inhaler triple therapy, higher ICS doses were not associated with a further reduction in exacerbations, whereas we found an increased risk of pneumonia. The use of inhaler devices delivering extrafine ICS particle was associated with a lower rate of exacerbations, resulting in lower overall HCRU costs.Keywords: COPD, triple-therapy, extrafine particle, exacerbations, pneumonia, health costs
- Published
- 2020